Armour Thyroid: How It Works, Dosing, and Why There Is No Self-Injection Technique

Is There a Self-Injection Technique for Armour Thyroid?

No. Armour Thyroid does not exist as an injectable preparation, and no FDA-approved natural desiccated thyroid (NDT) product can be administered by injection. The FDA-approved labeling for Armour Thyroid specifies an oral tablet formulation only. Any online claim describing an "NDT injection" or "desiccated thyroid shot" refers either to a compounded, unapproved preparation or to a different thyroid product entirely.

Why NDT Is Formulated Only as a Tablet

Desiccated thyroid extract is a biologically complex powder derived from porcine thyroid glands. It contains thyroglobulin, calcitonin, T1, T2, T3, and T4, along with connective-tissue proteins. Parenteral delivery of this matrix carries a meaningful risk of immunogenic reaction, and no manufacturer has pursued an injectable NDT through the FDA approval pathway. The FDA drug label for Armour Thyroid lists "tablet" as the sole dosage form.

What to Do If You Were Told an Injection Exists

If a telehealth provider or compounding pharmacy has offered you an injectable NDT product, ask to see the FDA approval number. Compounded thyroid injections are not FDA-approved and sit outside the safety and efficacy standards that govern Armour Thyroid tablets. Discuss the risk profile with a board-certified endocrinologist before proceeding.

How Armour Thyroid Works: Mechanism of Action

Armour Thyroid restores circulating thyroid hormone levels by supplying exogenous T4 (levothyroxine) and T3 (liothyronine) to patients whose own thyroid gland cannot produce adequate amounts. Both hormones bind to thyroid hormone receptors in the cell nucleus, altering gene transcription and regulating metabolism, thermogenesis, cardiac output, and neurological function. Thyroid hormone nuclear receptor signaling controls the expression of hundreds of downstream genes.

T4 Versus T3: Different Roles, Different Kinetics

T4 is largely a prohormone. Peripheral tissues convert it to the active T3 via 5'-deiodinase enzymes. In patients taking levothyroxine alone, this conversion sometimes falls short, particularly in those with DIO2 gene polymorphisms affecting type-2 deiodinase activity.

Armour Thyroid bypasses that conversion step for a portion of thyroid hormone replacement by delivering T3 directly. Each 60 mg (1 grain) tablet contains approximately 38 mcg of T4 and 9 mcg of T3, a ratio of roughly 4:1. Human thyroid glands secrete T4 and T3 at a ratio closer to 14:1, so NDT delivers a disproportionately high T3 load relative to normal physiology.

T3 peaks in serum within 2-4 hours of an oral NDT dose, then falls sharply due to its short half-life of roughly 24 hours. This produces a daily cycle of relative T3 excess followed by a trough, which some clinicians consider a disadvantage compared with the steady-state levels achieved with levothyroxine monotherapy.

The Pituitary Feedback Loop

When thyroid hormone levels are restored to the normal range, the hypothalamus reduces thyrotropin-releasing hormone (TRH) output, and the pituitary reduces TSH secretion. Clinicians use serum TSH as the primary monitoring parameter because TSH responds sensitively to small changes in circulating T4 and T3. A TSH below 0.5 mIU/L during NDT therapy suggests over-replacement and warrants dose reduction to avoid atrial fibrillation and accelerated bone loss. The American Thyroid Association guidelines (2014) recommend a TSH target of 0.4-4.0 mIU/L for most adults on thyroid hormone replacement, with tighter ranges in specific populations.

NDT Versus Levothyroxine: What the Evidence Shows

The comparison between Armour Thyroid and synthetic levothyroxine (LT4) is one of the most debated topics in thyroid medicine. Patients often report symptom differences that are not fully reflected in TSH values alone.

The Hoang 2013 Trial

The most frequently cited head-to-head study is Hoang et al. (J Clin Endocrinol Metab, 2013, N=70), a randomized crossover trial in which adults with hypothyroidism received either NDT or levothyroxine for 16 weeks each. Both treatments produced similar TSH suppression, and there was no statistically significant difference in quality-of-life scores on standardized instruments. However, 49% of participants preferred NDT at the end of the trial versus 19% preferring levothyroxine (P<0.001), and the NDT group lost a mean of 0.9 kg more body weight. The authors concluded that NDT "did not result in worse outcomes" than levothyroxine, and that patient preference was a clinically relevant consideration. PubMed: PMID 23539727.

The Peterson 2018 Survey Data

A large patient-survey study by Peterson et al. (Thyroid, 2018, N=12,146) found that patients using NDT or combination T4/T3 therapy reported significantly higher satisfaction scores and lower rates of residual hypothyroid symptoms than those on levothyroxine monotherapy. This was an observational, self-selected sample, so causation cannot be assigned, but the signal was consistent across age and sex subgroups. PubMed: PMID 29620972.

Guideline Positions

The 2014 American Thyroid Association guidelines state: "There is currently insufficient evidence to recommend the routine use of combination T4/T3 therapy or natural desiccated thyroid in preference to levothyroxine monotherapy." The guidelines do acknowledge that a subset of patients may have persistently low well-being on LT4 alone and that a trial of combination therapy may be appropriate after informed discussion.

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism similarly recommends levothyroxine as first-line therapy while recognizing NDT as an acceptable alternative in select patients. Endocrine Society guideline.

HealthRX Clinical Decision Framework: When to Consider NDT Over LT4

A reasonable clinical pathway for considering NDT uses three checkpoints:

1. The patient remains symptomatic (fatigue, cognitive fog, weight gain) despite TSH in the 0.5-2.5 mIU/L range on optimized levothyroxine for at least 6 months.
2. Free T3 is in the lower third of the reference range (<3.1 pg/mL in most labs) despite normal free T4, suggesting impaired peripheral conversion.
3. No contraindications are present (cardiovascular disease with arrhythmia risk, severe osteoporosis, or adrenal insufficiency not yet treated with hydrocortisone).

If all three conditions are met, a prescriber-supervised trial of NDT at an equipotent starting dose is a defensible clinical choice consistent with current evidence.

How to Take Armour Thyroid Correctly

Timing and Food Interactions

Take Armour Thyroid on an empty stomach, 30-60 minutes before the first meal of the day. Food does not block absorption entirely, but calcium-rich foods, high-fiber meals, and coffee can reduce bioavailability by 20-40%. A 2008 study in Thyroid (Benvenga et al.) showed that coffee taken simultaneously with levothyroxine reduced absorption by a mean of 36%; the interaction is expected to apply to the T4 component of NDT as well.

Iron supplements, calcium carbonate, and antacids containing aluminum or magnesium should be spaced at least 4 hours from the NDT dose. NIH Office of Dietary Supplements notes on thyroid-drug interactions confirm this separation requirement.

Starting Dose and Titration Schedule

Most prescribers begin NDT at 30 mg (0.5 grain) once daily and recheck TSH plus free T4 and free T3 at 4-6 weeks. The dose is increased by 15-30 mg increments until TSH reaches the target range and symptoms resolve. The average maintenance dose for most adults falls between 60 mg (1 grain) and 120 mg (2 grains) daily, though some patients require up to 180 mg.

Elderly patients (>65 years) and those with known or suspected coronary artery disease should start at 15 mg daily and titrate more slowly, over 8-12 weeks per increment, to avoid precipitating angina or arrhythmia.

Splitting the Daily Dose

Because T3 has a short half-life, some clinicians split the daily NDT dose into two administrations (e.g., two-thirds in the morning and one-third at noon) to blunt the T3 peak and reduce palpitations. This strategy is supported by pharmacokinetic reasoning rather than large randomized controlled trials. Patients who report mid-afternoon fatigue or morning palpitations may benefit from this approach.

Monitoring Armour Thyroid Therapy

Laboratory Testing Schedule

After each dose change, wait at least 4-6 weeks before rechecking labs. TSH alone is sufficient for stable, asymptomatic patients. When switching from levothyroxine to NDT, or when symptoms persist despite normal TSH, a full panel of TSH, free T4, and free T3 gives a more complete picture.

Bone density (DXA scan) is appropriate at baseline for postmenopausal women and men over 65 starting NDT, given the well-documented association between over-replacement and bone loss. The National Osteoporosis Foundation recommends periodic DXA monitoring in any patient on long-term thyroid suppression therapy.

Cardiac Monitoring

A resting ECG before starting NDT is reasonable for patients over 50 or with cardiovascular risk factors. Atrial fibrillation occurs in roughly 12-15% of patients who develop subclinical hyperthyroidism from over-replacement, based on data from the Rotterdam Study cohort. Any patient reporting palpitations, tachycardia, or chest discomfort during titration should hold the dose increase and contact their prescriber promptly.

Potential Side Effects and Risks of Armour Thyroid

Signs of Over-Replacement

Symptoms of excess thyroid hormone include heart palpitations, tremor, heat intolerance, unintentional weight loss, diarrhea, and insomnia. These typically appear within days of a dose increase due to the rapid absorption of the T3 component. A TSH below 0.1 mIU/L confirms over-replacement and warrants immediate dose reduction.

Long-term over-replacement carries two major risks. Atrial fibrillation risk rises roughly 3-fold when TSH is persistently suppressed below 0.1 mIU/L according to a meta-analysis by Collet et al. (Archives of Internal Medicine, 2012). Bone turnover increases measurably, with studies showing a 9% reduction in femoral neck bone density in pre-menopausal women after 10 years of suppressive therapy.

Signs of Under-Replacement

Persistent fatigue, cold intolerance, weight gain, constipation, dry skin, and cognitive slowing suggest the dose is too low. Free T3 in the lower third of the reference range alongside a rising TSH confirms under-replacement. Dose increments of 15-30 mg every 4-6 weeks resolve symptoms in most patients within 3-4 months.

Allergen and Ingredient Considerations

Armour Thyroid contains desiccated porcine thyroid, making it unsuitable for patients with pork allergies or those who avoid pork for religious or dietary reasons. Inactive ingredients include calcium stearate, dextrose, microcrystalline cellulose, sodium starch glycolate, and opadry white. Patients with celiac disease should note that the dextrose filler is typically corn-derived, but cross-contamination risk in manufacturing should be confirmed directly with AbbVie.

Who Should Not Take Armour Thyroid

Absolute Contraindications

The FDA label lists three absolute contraindications: untreated adrenal cortical insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the formulation. In adrenal insufficiency, starting thyroid hormone without concurrent corticosteroid replacement can precipitate an acute adrenal crisis by increasing the metabolic clearance of cortisol faster than the adrenal glands can compensate. Patients with suspected adrenal insufficiency must be tested and treated before NDT is initiated.

Relative Contraindications and Cautions

Cardiovascular disease (particularly unstable angina or recent MI), severe osteoporosis, pregnancy in women whose dose has not been optimized, and concurrent use of anticoagulants (warfarin sensitivity increases with rising thyroid hormone levels) all require careful prescriber oversight rather than outright avoidance.

Pregnancy increases thyroid hormone demand by 25-50%. Women on NDT who become pregnant should have TSH checked immediately and at 4-week intervals through the first trimester. The American College of Obstetricians and Gynecologists (ACOG) recommends a TSH target of <2.5 mIU/L in the first trimester for pregnant women on thyroid hormone replacement.

Drug Interactions With Armour Thyroid

Several common medications alter NDT effectiveness or are affected by thyroid hormone status.

Warfarin sensitivity increases when thyroid hormone is added or increased, because thyroid hormone accelerates the catabolism of clotting factors. The INR may rise by 10-40% within 2-3 weeks of a dose change, requiring closer anticoagulation monitoring.

Cholestyramine and colestipol bind T4 and T3 in the gut and reduce NDT absorption by up to 30% if taken within 4 hours. Proton pump inhibitors reduce gastric acid and impair dissolution of the tablet, though the clinical magnitude of this effect is smaller than with calcium or iron. NIH drug interaction data document the absorption-reducing effect of co-administered gastric acid suppressants on levothyroxine bioavailability, an effect applicable to the T4 fraction of NDT.

Sertraline, phenytoin, carbamazepine, and rifampin all increase hepatic clearance of thyroid hormones via CYP enzyme induction. Patients starting these drugs while on stable NDT may need a dose increase of 25-50 mcg T4 equivalent (approximately 15-30 mg NDT) within 4-8 weeks.

Switching From Levothyroxine to Armour Thyroid

Dose Conversion

A commonly used conversion ratio is 100 mcg of levothyroxine equivalent to approximately 60 mg (1 grain) of Armour Thyroid. This is an approximation only. Because NDT contains preformed T3, the effective biological potency is higher per microgram of T4 content. Many clinicians begin NDT at 80-90% of the mathematically calculated dose and titrate upward to avoid inadvertent over-replacement.

What to Expect During the Transition

Some patients report a temporary increase in energy and warmth within the first 1-2 weeks of switching, attributable to the T3 pulse from NDT. Others notice transient palpitations or mild anxiety in the first 7-10 days. These effects typically resolve as T4 levels stabilize. Recheck TSH, free T4, and free T3 at 4-6 weeks post-switch, not 6-8 weeks as is standard for a levothyroxine-only change, because the T3 component achieves steady state faster.